secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001214659-23-004684
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro initiates Phase I/IIA trial of ALZN002 for mild to moderate Alzheimer's dementia
--------------------------------------------------------------------------------

- Initiated Phase I/IIA clinical trial of immunotherapy vaccine ALZN002 for mild to moderate Alzheimer's dementia.
- Primary goal: determine appropriate dose for Phase IIB trial; Phase IIB expected within 3 months of initial data.
- Enrolling 20-30 subjects with mild to moderate morbidity; assesses safety, tolerability, efficacy vs placebo.
- CEO states ALZN002 may limit infusions, reduce adverse reactions, and improve cognitive outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923004684/0001214659-23-004684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923004684/p412308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-004684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer